Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
National National Cancer Drugs Fund Application Form – Bevacizumab for recurrent Cervical Cancer (2nd line treatment) Instructions to Consultants: Please fill in each section of the form electronically and save the document with your own file name. [If you continue typing the boxes will enlarge to contain the text]. Please send electronically to ______________________. Please also send copies to your Trust’s link accountant / corporate contracting team. Security of Patient Identifiable Information: The patient will be identified by their NHS number only. Please do not include any other patient identifiers for confidentiality reasons. All communication must be sent to the Cancer Drugs Fund Office via secure e mail accounts: that is from an nhs.net account to the ____________ account. Receipt of Application: The sender of the application will receive an acknowledgement, together with details of the unique Cancer Drugs Fund reference. Cancer Drugs Fund Policy: To check the status of a particular therapy please check the Cancer Drugs Fund Policy at _________________ Applications will be subject to Clinical Audit arrangements. Approved Treatment Required for Bevacizumab for recurrent cervical cancer – 1st line TICK All 8 conditions must be met 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Histologically confirmed carcinoma of the cervix. 3. Indication for 1st line palliative chemotherapy. 4. Primary stage IVB, recurrent, or persistent disease not amenable to curative treatment with surgery and/or radiotherapy. 5. Given with Paclitaxel and either Cisplatin or Carboplatin. 6. PS 0 or 1 7. No previous treatment with bevacizumab or other anti-VEGF therapy 8. No contra-indication to the use of bevacizumab 9. Bevacizumab dose to be 15mg/kg every 3 weeks Note: Bevacizumab is ONLY approved for use in combination with combination chemotherapy and is not approved for use as a single agent maintenance therapy Note: Bevacizumab should be discontinued due to toxicity or disease progression, whichever occurs first. Consultant Approval (email authority) Patient Consent Obtained (date of letter – copy to be retained on patient file) National Cancer Drugs Fund – Application Form 25 February 2014 Bevacizumab for Recurrent Cervial Cancer – 2nd line Page 1 Proposed Start Date for Therapy (add clinic date)*: Consultant details* (including signature or email confirmation) Name: Hospital: Address: Post Code: Telephone: Nhs.net Trust Pharmacist details of the Trust where the patient will be treated* Mandatory - NHS No*: Mandatory – Patients date of birth* Optional – Hospital No. Clinical Commissioning Group* Patient’s GP* (name, address, telephone) Name: Hospital: Address: Post Code: Telephone: Nhs.net NHS No: DOB: Hospital No: CCG Name: Name: Address: Post Code: ICD-10 Code* C53.9 – Malignant neoplasm of cervix uteri, unspecified HRG Code Completion of items marked with * is mandatory. Failure to complete these items may mean that payment is not made. National Cancer Drugs Fund – Application Form 25 February 2014 Bevacizumab for Recurrent Cervial Cancer – 2nd line Page 2